JP2023544382A - Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶 - Google Patents

Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶 Download PDF

Info

Publication number
JP2023544382A
JP2023544382A JP2023520277A JP2023520277A JP2023544382A JP 2023544382 A JP2023544382 A JP 2023544382A JP 2023520277 A JP2023520277 A JP 2023520277A JP 2023520277 A JP2023520277 A JP 2023520277A JP 2023544382 A JP2023544382 A JP 2023544382A
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
sequence
acid sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544382A5 (https=
Inventor
ハリリ、カメル
Original Assignee
テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2023544382A publication Critical patent/JP2023544382A/ja
Publication of JP2023544382A5 publication Critical patent/JP2023544382A5/ja
Priority to JP2025116242A priority Critical patent/JP2025148442A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023520277A 2020-10-02 2020-11-11 Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶 Pending JP2023544382A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116242A JP2025148442A (ja) 2020-10-02 2025-07-09 Ｒｎａによる単純ヘルペス ウイルスｉ型およびその他の関連するヒトヘルペス ウイルスの根絶

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063086648P 2020-10-02 2020-10-02
US63/086,648 2020-10-02
US202063109511P 2020-11-04 2020-11-04
US63/109,511 2020-11-04
PCT/US2020/059954 WO2022071974A1 (en) 2020-10-02 2020-11-11 Rna guided eradication of herpes simplex type i and other related human herpesviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116242A Division JP2025148442A (ja) 2020-10-02 2025-07-09 Ｒｎａによる単純ヘルペス ウイルスｉ型およびその他の関連するヒトヘルペス ウイルスの根絶

Publications (2)

Publication Number Publication Date
JP2023544382A true JP2023544382A (ja) 2023-10-23
JP2023544382A5 JP2023544382A5 (https=) 2023-12-05

Family

ID=80950788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023520277A Pending JP2023544382A (ja) 2020-10-02 2020-11-11 Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶
JP2025116242A Pending JP2025148442A (ja) 2020-10-02 2025-07-09 Ｒｎａによる単純ヘルペス ウイルスｉ型およびその他の関連するヒトヘルペス ウイルスの根絶

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116242A Pending JP2025148442A (ja) 2020-10-02 2025-07-09 Ｒｎａによる単純ヘルペス ウイルスｉ型およびその他の関連するヒトヘルペス ウイルスの根絶

Country Status (4)

Country Link
US (1) US20240271128A1 (https=)
EP (1) EP4221740A4 (https=)
JP (2) JP2023544382A (https=)
WO (1) WO2022071974A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199162A1 (en) * 2024-03-19 2025-09-25 Excision Biotherapeutics Inc Systems and methods for treatment of herpes simplex virus (hsv) infection
WO2025199160A1 (en) * 2024-03-19 2025-09-25 Excision Biotherapeutics Inc Systems and methods for delivery of crispr-cas gene editing machinery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153789A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
JP2018507183A (ja) * 2015-01-14 2018-03-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去
JP2018533375A (ja) * 2015-10-30 2018-11-15 エディタス・メディシン、インコーポレイテッド 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP3889260A1 (en) * 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
AU2017219605B2 (en) * 2016-02-15 2023-04-13 Temple University - Of The Commonwealth System Of Higher Education Excision of retroviral nucleic acid sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153789A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
JP2018507183A (ja) * 2015-01-14 2018-03-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去
JP2018533375A (ja) * 2015-10-30 2018-11-15 エディタス・メディシン、インコーポレイテッド 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物

Also Published As

Publication number Publication date
EP4221740A1 (en) 2023-08-09
JP2025148442A (ja) 2025-10-07
US20240271128A1 (en) 2024-08-15
WO2022071974A1 (en) 2022-04-07
EP4221740A4 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
JP7522088B2 (ja) 単純ヘルペス１型および他の関連するヘルペスウイルスのｒｎａガイド除去
JP7408284B2 (ja) 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物
JP7176737B2 (ja) レトロウイルス核酸配列の切除
JP2025148442A (ja) Ｒｎａによる単純ヘルペス ウイルスｉ型およびその他の関連するヒトヘルペス ウイルスの根絶
CA2319669A1 (en) Mutant herpes simplex viruses and uses thereof
JP2023544382A5 (https=)
US20230220361A1 (en) Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
CN121464217A (zh) 用于治疗KIF1A相关神经紊乱的靶向KIF1A错义突变的RNAi
WO2022145495A1 (en) Method for treating spinocerebellar ataxias (sca) by targeting atxn7 gene
WO2023147558A2 (en) Crispr methods for correcting bag3 gene mutations in vivo
CN116529363A (zh) I型单纯疱疹病毒和其它相关人类疱疹病毒的rna引导的清除
US20230279398A1 (en) Treating human t-cell leukemia virus by gene editing
Ventosa et al. Sustained FXN expression in dorsal root ganglia from a nonreplicative genomic HSV‐1 vector
US20220380812A1 (en) Crispr/cas9 system as an agent for inhibition of polyoma jc infection
US20230390367A1 (en) Genetic approach to suppress coronaviruses
US20230248810A1 (en) Method for treating alzheimer's disease by targeting mapt gene
Wu Studies of Neurotropism and Endonuclease Targeting of Varicella Zoster Virus Using a Cultured Human Neuron System
EP4605539A2 (en) Compositions and systems for herpes simplex virus packaging and uses thereof
WO2021168266A1 (en) Eradication of merkel cell polyomavirus
Georgiadis Viral vector-mediated RNA interference in the retina

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826